このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Comparison Between Outcomes of Closure of Idiopathic Macular Hole Using Autologus Tenon Capsule Graft and Internal Limiting Membrane Flap Techniques (Pilot Study)

2026年6月4日 更新者:Ain Shams University
The aim of this study is to compare the functional visual outcomes, anatomical closure rate and macular perfusion changes assessed by OCT and OCTA after surgical repair of macular hole using Tenon capsule graft versus ILM flap.

調査の概要

詳細な説明

Macular hole (MH) is a full-thickness defect of the neurosensory retina at the fovea, causing central visual loss. The incidence of idiopathic MH increases with age and is more common in females. Vitreomacular traction is the main pathophysiological factor leading to MH formation.

Pars plana vitrectomy with internal limiting membrane (ILM) peeling has been considered the standard technique for MH repair, achieving high anatomical closure rates. However, for large and refractory holes, conventional ILM peeling may not be sufficient.

The inverted ILM flap technique was developed as an alternative for large MHs (≥400 µm). This method allows the peeled ILM to be inverted and placed over the hole to serve as a scaffold for glial proliferation, enhancing closure rates and improving visual outcomes.

More recently, Tenon capsule graft has been introduced as an autologous biological scaffold for macular hole closure. Tenon tissue is rich in fibroblasts and extracellular matrix, which may promote retinal repair and facilitate closure in cases resistant to conventional approaches.

Optical coherence tomography (OCT) has become essential for evaluating macular hole dimensions, classifying stages, and confirming closure after surgery. It provides high-resolution images that allow detailed morphologic analysis.

Optical coherence tomography angiography (OCTA) enables noninvasive assessment of retinal and choroidal vasculature. Postoperative OCTA studies have shown changes in foveal avascular zone (FAZ) and vessel density in both superficial and deep plexuses, which may correlate with visual recovery.

Comparative studies between Tenon capsule graft and ILM flap using OCT and OCTA are limited, and further research is required to assess their relative efficacy in terms of anatomical closure, visual improvement, and vascular restoration. This study aims to address that gap.

The aim of this study is to compare the functional visual outcomes, anatomical closure rate and macular perfusion changes assessed by OCT and OCTA after surgical repair of macular hole using Tenon capsule graft versus ILM flap.

The study will be conducted in the ophthalmology department, at Ain Shams University Hospitals, Cairo, Egypt.

Inclusion criteria:

  • Patients diagnosed with idiopathic full-thickness macular hole
  • ≥400 µm in horizontal diameter

Exclusion criteria:

  • Media opacity preventing adequate OCT/OCTA imaging
  • Other retinal vascular pathology as retinal vascular occlusion
  • Intraoperative complications
  • Signal noise ratio using OCTA <6\10
  • Poor fixation of the patient

Group 1: Surgical repair of MH using Tenon capsule graft. Group 2: Surgical repair of MH using ILM Flap.

Sample Size:

Due to the novelty of the procedure and the rarity of cases needing surgical treatment and the expensive cost of intervention. This study is also a pilot study. This study is exempted from sample size calculation.

Study type: Prospective interventional .(Pilot study) Ethical Considerations: Written informed consent will be obtained from patients, after approval of the research ethics committee of the Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Study Tools

Preoperative examination :

All participants will have complete ocular examination including:

  • Best corrected visual acuity (BCVA) with Snellen E and then transformation to Log MAR
  • Slit-lamp examination
  • Fundus examination using 90 D lens
  • Intraocular pressure measurement by Goldmann applanation tonometry
  • Preoperative OCT to assess MH base diameter and narrowest diameter and thickness of edges to calculate MH indices
  • OCTA (OptovueInc, Fremont, CA). Sequential optical coherence tomography scans of a specific retinal region will be performed (central 3x3 Macular area Superficial, deep capillary plexus and choriocapillaris) and images will be processed in order to obtain motion contrast of erythrocytes within the vessel, thereby providing detailed imaging of the retinal capillary network. Capillary plexus density (CPD) of vessels in SCP, DCP and the size of the FAZ will be detected by OCTA en-face images.

Operative technique:

In all patients (Group A & B), PPV will be performed using a 23-gauge, transconjunctival, microincision vitrectomy system. Diluted triamcinolone acetonide (40 mg/ml) will be used to visualize the vitreous. After core vitrectomy, posterior hyaloid detachment will be attempted with the vitrectomy cutter in the suction mode. Then, the ILM will be stained using 0.05% Brilliant Blue G (OCUBLUE PLUS, India).

In Group A: tenon capsule graft will be attempted.

In Group B: free flap ILM peeling will be attempted

SF6 gas will be used as tamponade in both groups

More than one vitreoretinal surgeon will participate

Postoperative assessment:

Patients will be examined one day and three months after surgery. Postoperative assessment will include the following with each assessment: Full ophthalmic examination (UCVA, BCVA, anterior segment assessment, Goldman applanation tonometry measurement (in all follow up visits except 1st day postoperative), fundus examination).

Postoperative OCT to assess Anatomical closure and type of closure Post-operative macular scans by OCTA (OptovueInc, Fremont, CA). Sequential optical coherence tomography scans of a specific retinal region will be performed (central 3x3 Macular area Superficial, deep capillary plexus and choriocapillaris) and images will be processed in order to obtain motion contrast of erythrocytes within the vessel, thereby providing detailed imaging of the retinal capillary network. Capillary plexus density (CPD) of vessels in SCP, DCP and the size of the FAZ will be detected by OCTA en-face images

Primary outcome:

  • Improvement in BCVA

Secondary outcome:

  • OCT parameters of healing and type of healing
  • OCTA parameters of macular vessel density

Statistical Analysis and Statistical Package Data will be collected and analyzed with proper statistical tests.

研究の種類

介入

入学 (推定)

20

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:Mohammad Ahmed Rashad
  • 電話番号:+20 111 575 8888

研究場所

    • Abbassia
      • Cairo、Abbassia、エジプト
        • 募集
        • Ain Shams University

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Patients diagnosed with idiopathic full-thickness macular hole
  • ≥400 µm in horizontal diameter

Exclusion Criteria:

  • Media opacity preventing adequate OCT/OCTA imaging
  • Other retinal vascular pathology as retinal vascular occlusion
  • Intraoperative complications
  • Signal noise ratio using OCTA <6\10
  • Poor fixation of the patient

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
他の:ILM flap
ILM flap for treatment of macular hole as control

Prospective interventional study In all patients (Group A & B), PPV will be performed using a 23-gauge, transconjunctival, microincision vitrectomy system. Diluted triamcinolone acetonide (40 mg/ml) will be used to visualize the vitreous. After core vitrectomy, posterior hyaloid detachment will be attempted with the vitrectomy cutter in the suction mode. Then, the ILM will be stained using 0.05% Brilliant Blue G (OCUBLUE PLUS, India).

In Group A: tenon capsule graft will be attempted In Group B: free flap ILM peeling will be attempted SF6 gas will be used as tamponade in both groups More than one vitreoretinal surgeon will participate

他の名前:
  • Ilm flap
  • Tenon capsule graft
アクティブコンパレータ:Tenon capsule graft
Tenon capsule graft for treatment of macular hole

Prospective interventional study In all patients (Group A & B), PPV will be performed using a 23-gauge, transconjunctival, microincision vitrectomy system. Diluted triamcinolone acetonide (40 mg/ml) will be used to visualize the vitreous. After core vitrectomy, posterior hyaloid detachment will be attempted with the vitrectomy cutter in the suction mode. Then, the ILM will be stained using 0.05% Brilliant Blue G (OCUBLUE PLUS, India).

In Group A: tenon capsule graft will be attempted In Group B: free flap ILM peeling will be attempted SF6 gas will be used as tamponade in both groups More than one vitreoretinal surgeon will participate

他の名前:
  • Ilm flap
  • Tenon capsule graft

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
-Improvement in best corrected visual acuity (BCVA)
時間枠:3 months postoperative
Improvement in BCVA measured by snellen E chart then transformation to Logarithm of the minimum angle of resolution (Log MAR)
3 months postoperative

二次結果の測定

結果測定
メジャーの説明
時間枠
OCT
時間枠:3 months postoperative
To assess healing and closure of hole by OCT OptovueInc, Fremont, CA (qualitative measure to assess if the hole is closed or not)
3 months postoperative
OCTA
時間枠:3 months

superficial and deep capillary plexuses vessel density assessment by OCTA OptovueInc, Fremont, CA Sequential optical coherence tomography scans of a specific retinal region will be performed (central 3x3 Macular area Superficial, deep capillary plexus and choriocapillaris) and images will be processed in order to obtain motion contrast of erythrocytes within the vessel, thereby providing detailed imaging of the retinal capillary network. Capillary plexus density (CPD) of vessels in SCP, DCP and the size of the FAZ will be detected by OCTA en-face images.

(Density is measured as percentage and thickness is measured by micrometer )

3 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年11月9日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2028年1月1日

試験登録日

最初に提出

2026年3月9日

QC基準を満たした最初の提出物

2026年6月4日

最初の投稿 (実際)

2026年6月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月8日

QC基準を満たした最後の更新が送信されました

2026年6月4日

最終確認日

2026年3月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • FMASU MD351/2025

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する